

Martina Biggioggero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/732041/publications.pdf>

Version: 2024-02-01

43
papers

1,650
citations

304602

22
h-index

289141

40
g-index

44
all docs

44
docs citations

44
times ranked

2887
citing authors

#	ARTICLE	IF	CITATIONS
1	Baricitinib for COVID-19: a suitable treatment?. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1012-1013.	4.6	178
2	The geoepidemiology of the antiphospholipid antibody syndrome. <i>Autoimmunity Reviews</i> , 2010, 9, A299-A304.	2.5	159
3	Sex and Management of Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 333-345.	2.9	126
4	Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 57-70.	2.0	99
5	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1593-1603.	2.0	85
6	Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. <i>Rheumatology</i> , 2014, 53, 1664-1668.	0.9	70
7	Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an "anchor" drug?. <i>Autoimmunity Reviews</i> , 2014, 13, 1102-1108.	2.5	70
8	Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2014, 10, 35-43.	3.5	70
9	Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. <i>Arthritis Care and Research</i> , 2016, 68, 432-439.	1.5	69
10	The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. <i>Autoimmunity Reviews</i> , 2017, 16, 1185-1195.	2.5	67
11	Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. <i>Drugs in Context</i> , 2019, 8, 1-12.	1.0	55
12	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	1.6	45
13	Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. <i>Drugs</i> , 2019, 79, 1741-1755.	4.9	39
14	IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 900-904.	0.5	37
15	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 290.	1.6	37
16	Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 573-581.	1.9	33
17	Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. <i>Arthritis Care and Research</i> , 2017, 69, 867-874.	1.5	32
18	Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. <i>Clinical Rheumatology</i> , 2017, 36, 1747-1755.	1.0	31

#	ARTICLE	IF	CITATIONS
19	Ten-Year Drug Survival of Anti-TNF Agents in the Treatment of Inflammatory Arthritides. Drug Development Research, 2014, 75, S38-41.	1.4	30
20	Transforming growth factor β 1 in the pathogenesis of autoimmune congenital complete heart block: Lesson from twins and triplets discordant for the disease. Arthritis and Rheumatism, 2006, 54, 356-359.	6.7	25
21	Type I interferon therapy and its role in autoimmunity. Autoimmunity, 2010, 43, 248-254.	1.2	25
22	Treatment Comparison in Rheumatoid Arthritis: Head-to-Head Trials and Innovative Study Designs. BioMed Research International, 2014, 2014, 1-17.	0.9	25
23	The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors. BioMed Research International, 2019, 2019, 1-8.	0.9	24
24	Cutting-Edge Issues in Coronary Disease and the Primary Antiphospholipid Syndrome. Clinical Reviews in Allergy and Immunology, 2013, 44, 51-56.	2.9	21
25	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. Joint Bone Spine, 2014, 81, 508-512.	0.8	21
26	Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Design, Development and Therapy, 2017, Volume11, 211-223.	2.0	17
27	Sarilumab: patient-reported outcomes in rheumatoid arthritis. Patient Related Outcome Measures, 2018, Volume 9, 275-284.	0.7	14
28	Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients. Annals of the Rheumatic Diseases, 2021, 80, e75-e75.	0.5	14
29	The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. Drug Design, Development and Therapy, 2018, Volume 12, 1421-1429.	2.0	13
30	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. Journal of International Medical Research, 2016, 44, 113-118.	0.4	12
31	The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. BioMed Research International, 2018, 2018, 1-11.	0.9	12
32	The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 213-223.	1.2	11
33	Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. Annals of the Rheumatic Diseases, 2015, 74, e5-e5.	0.5	11
34	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. Drug Design, Development and Therapy, 2017, Volume 11, 1969-1978.	2.0	11
35	Structural integrity versus radiographic progression in rheumatoid arthritis: Figure 1. RMD Open, 2015, 1, e000064.	1.8	10
36	Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Expert Review of Clinical Immunology, 2021, 17, 561-571.	1.3	10

#	ARTICLE	IF	CITATIONS
37	Mild cognitive impairment in psoriatic arthritis. <i>Medicine (United States)</i> , 2021, 100, e24833.	0.4	9
38	The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrolment: Data from a systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 730-737.	1.6	8
39	Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. <i>Modern Rheumatology</i> , 2018, 28, 542-549.	0.9	8
40	The challenging definition of naïve patient for biological drug use. <i>Autoimmunity Reviews</i> , 2015, 14, 543-546.	2.5	6
41	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. <i>Clinical Rheumatology</i> , 2021, 40, 4039-4047.	1.0	3
42	Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 661-670.	1.3	2
43	Regulation of auto-antibody production by persisting auto-immune complexes on follicular dendritic cells. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A38.1-A38.	0.5	0